# A Clinical Investigation to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease

> **NCT05206084** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Biotyx Medical (Shenzhen) Co., Ltd.** · enrollment: 518 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DEVICE:** Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS)
- **DEVICE:** Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System

## Key facts

- **NCT ID:** NCT05206084
- **Lead sponsor:** Biotyx Medical (Shenzhen) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-10
- **Primary completion:** 2024-12-29
- **Final completion:** 2028-01
- **Target enrollment:** 518 (ACTUAL)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05206084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05206084, "A Clinical Investigation to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05206084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*